By excluding industry’s glyphosate studies, IARC dismisses most relevant research says critic

Print Friendly, PDF & Email

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

A little more than a year ago, the International Agency for Research on Cancer (IARC), reviewed studies on glyphosate and concluded it’s a “probable human carcinogen.”

IARC’s findings “baffled” the scientific community, including regulators, Hank Campbell, president of the American Council on Science and Health, told Legal Newsline. . . .

. . . .

When IARC puts a panel together, it won’t call on experts from the industry — or those who have consulted for the industry, he said.

That leaves out a number of smart people in a field where consulting with the industry is the mark of a high-caliber academic, he added.

Related article:  EPA panel begins evaluation of carcinogenicity of glyphosate

Leaving out industry studies also dismisses a substantial portion of relevant research.

“Obviously (regulatory agencies) also put the burden of proof on companies to prove something is safe,” he said. “Companies must pay for studies to show that, not taxpayers. So if you say you won’t allow industry studies, you leave out everything except academic epidemiology.”

Read full, original post: Controversial body’s glyphosate research isn’t reliable, critics say

Outbreak Featured
Infographic: Growing human embryos — How long should researchers watch human development play out in a dish?

Infographic: Growing human embryos — How long should researchers watch human development play out in a dish?

In May, the International Society for Stem Cell Research (ISSCR) released new guidelines that relaxed the 14-day rule, taking away ...
Are GMOs and pesticides threatening bees?

Are GMOs and pesticides threatening bees?

First introduced in 1995, neonicotinoids ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.